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importers of antimicrobial medicines are: India (25,8%), Russia (16%), China (9.7%), 
Ukraine (9.7 %), France (6.5 %), and manufacturers from other countries consisted 
- 3,2%. CONCLUSIONS: A large part of the drugs purchased within the guaran-
teed volume of free medical aid in the Republic of Kazakhstan consist from basic 
beta-lactam antibiotics. In the list were presented the outdated drugs (gentamicin), 
which is not recommended for use. Predominant drug are drugs from domestic 
pharmaceutical companies.
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OBJECTIVES: Despite all the control efforts, Malaysia has yet to effectively reduce 
the incidence rate of tuberculosis(TB). TB is not only highly contagious but also 
causing a significant economic burden in the order of USD16 million/year as 
reported by World Health Organization(WHO) in 2014. This study aimed to evalu-
ate the economic impact of TB control in Malaysia using a dynamic transmission 
model. METHODS: Prior to model building, a disease burden study was performed 
in the state of Selangor representing 18% of the Malaysian population. Identified 
patient medical records from public hospitals and clinics were randomly selected 
for study. All direct costs of TB management were captured for analysis. A dynamic 
transmission model was built to project future disease and economic burdens over 
a 10-year period. The study was performed from a government perspective. All costs 
are expressed as USD median (interquartile range). A 3% discount rate was used 
for projections. RESULTS: A total of 436 successfully treated cases were included 
in this study. Of these, 195(44.7%) cases required hospitalisation during treatment 
period. USD616(487-763)/patient was used for non-hospitalisation cases compared 
to USD1,848(1,164-3,284)/patient for those requiring hospitalisation representing 
a 3-fold increase. 119 incomplete treatment cases were selected for comparison. 
USD337(193-902)/patient was used for these incomplete cases. Our model suggests 
that the total TB cases will increase by 65% in 10 years’ time. Using the baseline TB 
population in 2011, an estimated total of USD22.9 million(15.5-37.6 million)/year was 
used for direct medical costs. Based on a local estimated 6.9% incompletion treat-
ment rate, an extra USD5.3 million(3.5-8.6 million)/year (22.9% increase) would be 
required by 2021. CONCLUSIONS: Our findings are consistent with WHO report. In 
Malaysia, hospitalisation appears to be the major cost driver for TB patients receiv-
ing treatment. Healthcare strategies such as early detection, increased awareness of 
TB and improved compliance may potentially reduce TB health budget.
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OBJECTIVES: Differences in vaccine schedules may result in additional costs beyond 
the differences due to pricing variation between two products. There are two oral 
rotavirus vaccines approved for use in Canada; one vaccine is approved as a two-
dose schedule while the other is approved as a three-dose schedule. The objective of 
this study is to explore the cost of administration of a single dose of either rotavirus 
vaccine in each Canadian province as well as for the country overall. METHODS: Two 
extremes were considered: Every dose administered by a physician either (i) requires 
a visit solely for that purpose (cost = administration + visit), or (ii) occurs as part of 
a regular visit (cost = administration only). All costs were derived from the relevant 
fee for service agreement of each province and territory in Canada. Assumptions 
included 90% vaccine coverage across each province’s 2013 birth cohort and no 
significant changes since 2007 to the ratio of physicians to public health nurses 
(PHN) administering vaccines in each province. Delivery by PHN was assumed to 
incur no cost. RESULTS: Scenarios (i) and (ii) above yielded administration costs 
of $6.4M and $600k, respectively, per vaccinated Canadian cohort. Provinces with 
high percentage of physician delivery accounted for the majority of this cost in 
both Scenario (i) (NL: $128.6k, NB: $279.3k, NS: $312.1k, QC: $832.5k, ON: $3.8M, MB: 
$386.3k, BC: $544.1k) and Scenario (ii) (NB: $60.4k, NS: $114.2k, QC: $258.8k, MB: 
$85.1k, BC: $72.8k). CONCLUSIONS: Administration fees can be a costly factor in 
universal immunization schedules. As such, it is essential to account for the differ-
ences in approved administration schedule when evaluating vaccines during the 
assessment of publically funded program implementation.
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OBJECTIVES: Infections caused by multi-drug resistant (MDR) Acinetobacter bau-
mannii (AB) are an increasing global problem. Several studies examining outcomes 
and resource utilization associated with MDRAB have been conducted; however, 
findings are inconsistent. The purpose of this research was to identify and charac-
terize available research concerning resource utilization associated with MDRAB, 
assess strengths and weaknesses of the available research and identify future 
research priorities. METHODS: A systematic review of the literature was conducted 
using MEDLINE and electronically available conference abstracts. Articles were con-
sidered relevant if they reported resource utilization or cost information comparing 
MDRAB patients to controls. Controls could include susceptible AB, other organisms, 
or uninfected patients. RESULTS: Initial searches of the literature returned 204 
potential citations for inclusion. Title and abstract review excluded 171 articles, 
and full-text review excluded 20 additional articles, leaving a total of 13 articles 
eligible for data abstraction and review. Length of stay (LOS) was reported in nine 
PIN94
ProjEctINg chaNgEs IN total Days of thEraPy (Dot) IN PatIENts 
hosPItalIzED for acutE bactErIal skIN aND skIN structurE INfEctIoN 
(absssI)
Berger A.1, Kauf T.2, Oster G.3
1Evidera, Lexington, MA, USA, 2Cubist Pharmaceuticals, Lexington, MA, USA, 3Policy Analysis 
Inc. (PAI) and Managing Co-Director, MINERVA Health Economics Network, Brookline, MA, USA
OBJECTIVES: Most patients admitted to hospital for ABSSSI complete antibacte-
rial treatment following discharge. This study examined the potential impact of 
tedizolid versus linezolid on antibacterial DOT, based on real-world inpatient use 
of linezolid in patients hospitalized for ABSSSI, and two pivotal phase 3 studies of 
patients with ABSSSI that demonstrated comparable efficacy and safety between 
a 6-day course of tedizolid (once daily) and a 10-day course of linezolid (twice 
daily). METHODS: Duration of in-hospital therapy for ABSSSI was based on analyses 
of an electronic database containing comprehensive clinical records on ~38 million 
inpatient admissions from > 100 contributing general, acute-care US hospitals. All 
patients aged ≥ 18 years admitted during 2011 with a principal diagnosis consistent 
with ABSSSI who received ≤ 10 inpatient DOT with linezolid were identified. Total 
DOT for linezolid and tedizolid (i.e., inpatient + outpatient) were assumed to be 10 
and 6 days, respectively. Patients receiving < 10 days of in-hospital therapy with lin-
ezolid were assumed to receive the remainder as outpatients; corresponding values 
for tedizolid were estimated assuming a 6-day DOT. Patients receiving ≤ 6 inpatient 
DOT with linezolid were modeled to receive the same number of inpatient days of 
tedizolid; patients with > 6 days of in-hospital therapy with linezolid were modeled 
as completing a course of tedizolid in hospital. RESULTS: Among the 3,734 ABSSSI 
patients who met study entry criteria, 153 (4%) received linezolid. Mean inpatient 
DOT was 3.7 days; consequently, expected duration of outpatient therapy was 6.3 
days. Use of tedizolid instead of linezolid was estimated to reduce average inpatient 
DOT by 0.2 days and outpatient DOT by 3.8 days. CONCLUSIONS: Based on real-
world use of linezolid for ABSSSI and findings from tedizolid pivotal trials, use of 
tedizolid in hospitalized patients with ABSSSI may substantially reduce mean total 
DOT compared with linezolid, primarily on an outpatient basis.
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OBJECTIVES: The objective of this study is to examine the decisive factors associated 
with the use of antiretroviral therapy (ART) among a Human Immunodeficiency 
Virus (HIV) infected population utilizing Andersen’s Behavioral Model. METHODS: 
This study is a retrospective data analysis of individuals infected with HIV in panels 
14 to 16 of the Medical Expenditure Panel Survey in years 2009 to 2012. A logistic 
regression analysis was conducted to evaluate the association between ART usage 
and the factors nested in Andersen’s Behavioral Model, which includes predispos-
ing, enabling and need components. RESULTS: For predisposing characteristics, 
patients taking ART were slightly older (age: 46.14±0.98) than patients not taking 
ART (age: 43.34±0.91). Being a male and African American was highly associated with 
the use of ART, as compared to being a female or white (P value: < 0.0001; 0.00119). 
People living in the Northeast were more likely to take ART than individuals living 
in other regions in the United States (P value: 0.0032). Among enabling components, 
difficulty in receiving medical care and having non-public insurance coverage were 
associated with not taking ART (P value: 0.0851; 0.0013). Having private insurance 
coverage was positively correlated with nonuse of ART (odds ratio: 0.190; 95% CI: 
0.047-0.779; P value: 0.00003). However, family income was not associated with the 
use of ART among the HIV-infected population. With respect to the health status 
in the need component, using ART was associated with reported improved health 
status in general, compared with those not using ART; however, the association was 
not statistically significant. CONCLUSIONS: Predisposing and enabling factors were 
found to be significantly associated with ART usage; however, need factors were not 
found to be significant. More effort is needed to improve the healthcare utilization 
inequality among minority populations.
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OBJECTIVES: Study of drug coverage in the Republic of Kazakhstan as one of the 
most important components of medical care and an important measure of social 
support of citizens. METHODS: The List of drugs for purchase in 2014 by Single 
Distributor “SK-Pharmacy “ was analyzed. The percentage of antimicrobial drugs 
for certain groups of antibiotics and synthetic antibacterial agents of different 
chemical structure was studied. The analysis of drugs from domestic and foreign 
drug manufacturers was performed. RESULTS: Among all antibacterial drugs a big 
part consisted from antibiotics - 71%, synthetic chemotherapeutic drugs amounted 
to 29%. Of the total number of antibiotics the proportion of beta-lactam antibiot-
ics amounted to 61,36%, macrolides and azalides – to 15,91%, aminoglycoside – to 
6,82%, tetracyclines and glycopeptides to 2,27%, antibiotics from other groups - 
to11,36%. Among beta-lactam antibiotics a big part consisted from semisynthetic 
penicillins with wide spectrum - 29.6%, mainly amoxicillin and its “secured forms”. 
Cephalosporins consisted 51.85% of the total number of antibiotics, and were bought 
mainly drugs of 3rd generation. Carbapenems amounted to 11.11%, monobactams 
were not bought. From the group of aminoglycosides following drugs were bought: 
amikacin, kanamycin, streptomycin, gentamicin. Synthetic antibacterial drugs of 
different chemical structures were represented mainly by fluoroquinolones (66,67%): 
moxifloxacin, ofloxacin, norfloxacin, pefloxacin , ciprofloxacin. The half (50%) of 
procured medicines are products of domestic pharmaceutical companies. The main 
